Conflicts of Interest:
Author K. Walkovich discloses the following potential conflicts of
interest: she is the local principal investigator for the Mavorixafor
trial (sponsored by X4 Pharmaceuticals); she is a member of the steering
committee for Sobi; and she is on the advisory board for Sobi, Pharming,
AstraZeneca, Horizon, and X4 Pharmaceuticals. None of these are relevant
to this study however. The remaining authors have no relevant conflicts
of interest to disclose.
References :
1. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N
Engl J Med . Aug 30 2018;379(9):856-868. doi:10.1056/NEJMra1607548
2. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves
outcome in multisystem Langerhans cell histiocytosis. Blood . Jun
20 2013;121(25):5006-14. doi:10.1182/blood-2012-09-455774
3. Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine
in refractory multisystem Langerhans cell histiocytosis: results of an
international phase 2 study. Blood . Sep 17 2015;126(12):1415-23.
doi:10.1182/blood-2015-03-635151
4. Eckstein O. Randomization of cytarabine monotherapy versus
standard-of-care vinblastine/prednisone for frontline treatment of
Langerhans Cell Histiocytosis (TXCH LCH0115). ClinicalTrials.gov
identifier: NCT02670707. Updated June 12, 2023. Accessed July 7, 2023.
https://www.clinicaltrials.gov/study/NCT02670707
5. Rabin RC. Faced with a drug shortfall, doctors scramble to treat
children with cancer. New York Times . October 14, 2019. Accessed
July 7, 2023.
https://www.nytimes.com/2019/10/14/health/cancer-drug-shortage.html
6. McBride A, Hudson-DiSalle S, Pilz J, et al. National Survey on the
Effect of Oncology Drug Shortages in Clinical Practice: A Hematology
Oncology Pharmacy Association Survey. JCO Oncol Pract . Aug
2022;18(8):e1289-e1296. doi:10.1200/OP.21.00883
7. Arem H, Moses J, Nekhlyudov L, et al. Oncology provider experiences
during the COVID-19 pandemic. PLoS One . 2022;17(7):e0270651.
doi:10.1371/journal.pone.0270651
8. Maloney KW, Devidas M, Wang C, et al. Outcome in Children With
Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s
Oncology Group Trial AALL0331. J Clin Oncol . Feb 20
2020;38(6):602-612. doi:10.1200/JCO.19.01086
9. Angiolillo AL, Schore RJ, Kairalla JA, et al. Excellent Outcomes With
Reduced Frequency of Vincristine and Dexamethasone Pulses in
Standard-Risk B-Lymphoblastic Leukemia: Results From Children’s Oncology
Group AALL0932. J Clin Oncol . May 1 2021;39(13):1437-1447.
doi:10.1200/JCO.20.00494
10. Eckstein OS, Bernhardt MB, Hood CG, Karri V, Kralik SF, McClain KL.
Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine.Pediatr Hematol Oncol . Jan 10 2023:1-9.
doi:10.1080/08880018.2022.2137609
11. Liliemark JO, Paul CY, Gahrton CG, Peterson CO. Pharmacokinetics of
1-beta-D-arabinofuranosylcytosine 5’-triphosphate in leukemic cells
after intravenous and subcutaneous administration of
1-beta-D-arabinofuranosylcytosine. Cancer Res . May
1985;45(5):2373-5.
12. North American Consortium for Histiocytosis. LCH-IV, international
collaborative treatment protocol for children and adolescents with
Langerhans Cell Histiocytosis. ClinicalTrials.gov identifier:
NCT02205762. Updated March 23, 2023. Accessed July 7, 2023.
https://www.clinicaltrials.gov/study/NCT02205762